Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HSV-2 alphavaccine
- Development stage
- Unknown
- Lead developer
- AlphaVax
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
HSV-2 alphavaccine (AVX-201) is a viral replicon particle (VRP) vaccine developed by AlphaVax for the prevention and treatment of herpes simplex virus type 2 (HSV-2) infections. The vaccine utilizes a propagation-defective RNA replicon vector derived from the Venezuelan Equine Encephalitis (VEE) virus. This platform is designed to deliver genetic sequences encoding HSV-2 antigens directly into dendritic cells, where they are expressed to stimulate a potent and balanced immune response, including both neutralizing antibodies and cytotoxic T-cell activity. While the platform showed promise in early-stage clinical trials, the development status of the HSV-2 program has become uncertain following AlphaVax's operational changes.
- Other names
- AlphaVax HSV-2 vaccineHSV-2 VRP vaccineHSV2 VRP vaccineHSV 2 VRP vaccineHSV-2 RNA particle vaccineHSV2 RNA particle vaccineHSV 2 RNA particle vaccine
Beyond the preview
Go deeper on HSV-2 alphavaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HSV-2 alphavaccine.